in the forefront of the battle against emerging infectious diseases avraham shimon marilus ceo dorit...
TRANSCRIPT
In the forefront of the battle against emerging infectious diseases
Avraham Shimon Marilus CEODorit Arad CSO and Founder
Mission
Be ready to
Rapidly detectPrevent the spreadProvide better treatment
for infectious diseases particularly those that impose
world pandemics threat
MND’s Platform
Novel (Based on viral enzyme detection)
Rapid (only 3 minutes detection)Detection of live viruses
For pandemic causing viruses to prevent
their spread
For existing viruses to
provide a better care
MND diagnostics
• Founded in2004 as an incubator company
• Established a collaboration with BMD (Biomedical Diagnostic, France)
• Recently completed first round of $4.7 million financing from Swiss investors
• Achieved proof of concept on the detection of enterovirus meningitis in CSF samples
Manpower: 10 persons.
Situated in Science Park Nes-Ziona.
Business Development The BDC Group
Prof Max Herzberg Prof. Christian Policard Ms. Nicole Rieunier-Burle
Clinical StudiesClinical StudiesDavid Greenberg M.D., David Greenberg M.D., Medical director, SorokaMedical director, SorokaHospital, Israel. Hospital, Israel. Prof. Dana Wolf, Hadassah Prof. Dana Wolf, Hadassah
Hospital, IsraelHospital, Israel
Mr. AvrahamMr. Avraham Marilus CEO and Chairman Marilus CEO and Chairman Dr. Dorit Arad – CSO and founderDr. Dorit Arad – CSO and founder
Dr. Ouriel Faktor VP R&DDr. Ouriel Faktor VP R&DProf. Max Herzberg - DirectorProf. Max Herzberg - Director
The MND Team
Development TeamDevelopment Team
Yaniv Nevo Ph.DYaniv Nevo Ph.D
Assaf Ezra Assaf Ezra
Ofer Nusbaum Ph.D Ofer Nusbaum Ph.D
Gilad WainrebGilad Wainreb
The Technology:Specific Enzymatic Based
assay
(I)
(II)
++
Peptide colorPeptide colorreactionreaction
viral enzymeviral enzyme
Quenched Quenched tag tag
SpecificSpecificsequencesequenceDetectorDetector
peptide peptide
(III)
Advantages
New IP – new niche in the crowded diagnostics arena Detecting virus in their active stage, unlike RT-PCR
and immunoassays Rapid detection relative to PCR (minutes relative to
hours) proprietary molecules Detection procedure is simple Inexpensive Could be adjusted to hand-held field usage (airports
and public places)
Business Model
MNDQPT
Technology
BMD Multiplex MeningitisPartner – Avian Flu (poultry)
MND single testMeningitis
Partner – emerging pandemic kitfor outbreak control
MND CMV
MND Avian Flu (Humans)
Combination of product development, licensing and partnering leverages MND’s IP and knowhow to its fullest
Current clinical Current clinical DevelopmentDevelopment
Meningitis Rapid Detection Kit
• The need for DetectionThe need for Detection• Each year in the United States 10 million to 15 million illnesses are
attributed to Enterovirus• 300,000 Lumbar Punctures are performed in the US every year. This
number will grow when there will be a fast detection tool to diagnose the disease.
• Current Gold Standard• The “gold standard” for Enterovirus detection is Tissue culture which
takes 3 days. RT-PCR takes 5-24 hours
• Current Development StatusCurrent Development Status• Proof of concept completed in 2007• Pre-clinical studies planned for Q3 2008• Over 100 clinical CSF samples tested successfully
Market Opportunities
1. Persistent viruses (Meningitis, Enterovirus, CMV and Rhinovirus)
2. Emerging viruses (Avian Flu, SARS).
Group A
CMV
Enteroviruses
Hepatitis A
Polio
Rhino Virus
Avian flu
Influenza A,B
SARS
Group B
Caliciviruses
EBV
Hepatitis C
Hepatitis E
Herpes A, B
West Nile
HIV
Group C
Adeno Virus
Para Influenza1,2,3Group D
RSV
12
IP & knowhow
Innovative MND’s intellectual property includes three pending patents on the detection method, compositions of matters for a wide range of viruses including HCV and detection of avian influenza.
KnowhowUnique molecular design techniques (QCT) enable the
creation of effective molecules, specific to each disease agent, for treatment and detection. Experience in the development of rapid testing formats
Creating leverage through MND’s novel IP
13
Company Goals 2008-2010
Launch Meningitis Rapid Detection Kit to market in 2009.
Advance MND platform and pipeline products for the detection of: Avian Influenza, CMV, HCV and Foot and Mouth disease.
Complete co-development of a Multiplex Detection Kit with BMD (BioMedical Diagnostics, France).
Establish strategic partnerships with leading Pharma.
Summary
MND technology has the potential to become a gold standard for Rapid detection, in non-lab conditions, of active infectious viruses such as: ENV, RHV, CMV, HCV, MFV, Inf.
MND broad technology can be expanded for development of Cancer markers and Blood coagulations diseases, and enrich the company pipeline.
MND relevant market segments - $13.3B (~34%) of the annual $40B IVD market.
We expect to launch our first product for meningitis detection in a year in third quarter of 2009.
Thank you!